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Abstract
Staphylococcus aureus possesses an impressive arsenal of complement evasion proteins that help
the bacterium escape attack of the immune system. The staphylococcal complement inhibitor (SCIN)
protein exhibits a particularly high potency and was previously shown to block complement by acting
at the level of the C3 convertases. However, many details about the exact binding and inhibitory
mechanism remained unclear. In this study, we demonstrate that SCIN directly binds with nanomolar
affinity to a functionally important area of C3b that lies near the C terminus of its β-chain. Direct
competition of SCIN with factor B for C3b slightly decreased the formation of surface-bound
convertase. However, the main inhibitory effect can be attributed to an entrapment of the assembled
convertase in an inactive state. Whereas native C3 is still able to bind to the blocked convertase, no
generation and deposition of C3b could be detected in the presence of SCIN. Furthermore, SCIN
strongly competes with the binding of factor H to C3b and influences its regulatory activities: the
SCIN-stabilized convertase was essentially insensitive to decay acceleration by factor H and the
factor I- and H-mediated conversion of surface-bound C3b to iC3b was significantly reduced. By
targeting a key area on C3b, SCIN is able to block several essential functions within the alternative
pathway, which explains the high potency of the inhibitor. Our findings provide an important insight
into complement evasion strategies by S. aureus and may act as a base for further functional studies.
The bacterium Staphylococcus aureus is a widely disseminated and persistent human pathogen
that has a longstanding and increasingly negative impact on human health. It is a primary
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etiologic agent of numerous disorders that range from the seemingly mild, such as skin and
soft tissue infections, to several potentially fatal conditions, including bacteremia, necrotizing
pneumonia, and endocarditis, as well as infections associated with implanted medical devices,
such as intravascular catheters, pacemakers, and delivery pumps (1). Treatment options for
staphylococcal disease have become more limited in recent years in large part because of the
proliferation of antibiotic-resistant strains of the organism. Thus, it has become clear that if
effective therapies and preventative measures against S. aureus infection are to be provided in
the future, a more complete understanding of this complex organism and how it interacts with
various human physiological systems is required today.
Perhaps one of the most striking features of S. aureus biology is its ability to colonize and
survive in a number of unique microenvironments within its host. This ability contributes to
its propensity to form long-lasting and repetitive infections (1), even in the presence of a robust
immune response. Over the last several years, studies from a number of different investigators
have revealed that S. aureus achieves this ability in part by producing a variety of
immunomodulators that affect both arms of the host immune system (2,3). Because the
complement system is an essential first line of defense against invading microbial pathogens
and is a central component of immunity, it is a prime target of staphylococcal immune evasion
strategies (4). In fact, S. aureus secretes at least 10 unique proteins that disrupt processes
essential to either complement initiation or amplification, or downstream chemotactic events
that depend upon the anaphylatoxins generated during complement activation (reviewed in
Ref. 4–6). Very recently, it was discovered that S. aureus may even disrupt the activation of
adaptive immune responses by inhibiting the interaction of C3d with complement receptor
(CR)4 type 2 (7).
Among this suite of immune evasion factors, the staphylococcal complement inhibitor (SCIN)
family is comprised of four small (~9.8 kDa), secreted proteins that adopt a three-helix bundle
fold (8,9). SCIN proteins are structurally homologous to the IgG-binding modules of
staphylococcal protein A (4,9), and are related more distantly to the other complement
inhibitors extracellular fibrinogen-binding protein (Efb) (2,10), Efb homologous protein (Ehp)
(11), and staphylococcal Ig-binding protein (Sbi) (12) from the same organism (4). Within the
SCIN family, three of the members (SCIN-A, SCIN-B, and SCIN-C) inhibit complement
activation, whereas a fourth form, open reading frame (ORF)-D, lacks this activity (9). This
observation, coupled with the higher levels of sequence identity among SCIN-A, SCIN-B, and
SCIN-C, was used by Rooijakkers et al. (9) to map the active site of the functional SCIN family
members to an 18 residue segment comprised of Leu31-Gly48. According to the crystal structure
of SCIN-A, this active region spans the extreme C-terminal portion of helix α1 through
approximately the N-terminal half of helix α2.
The effectiveness of the complement-mediated immune response relies on the rapid recognition
of microbial cell surface patterns by the classical, lectin, or alternative pathway (of complement
activation). All pathways lead to the cleavage of complement component C3 into its active
fragments C3a and C3b by bimolecular C3 convertase complexes. Whereas C3a acts as a potent
immunomodulator, C3b becomes covalently attached to foreign surfaces. Deposited C3b is not
only responsible for the self-amplification of the complement response via the alternative
pathway, but it also induces a variety of downstream immune responses. The SCIN proteins
are of particular interest for complement evasion because they are capable of potent inhibition
of all three complement initiation pathways (8,13). This feature stands in contrast with the
4Abbreviations used in this paper: CR, complement receptor; SCIN, staphylococcal complement inhibitor; SPR, surface plasmon
resonance; ORF, open reading frame; Efb, extracellular fibrinogen-binding protein; Ehp, Efb homologous protein; fB, factor B; fD, factor
D; fH, factor H; fI, factor I; ITC, isothermal titration calorimetry; MG, macroglobulin domain; SAXS, small angle X-ray scattering; Sbi,
staphylococcal Ig-binding protein; TED, thioester-containing domain.
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other complement inhibitors Efb, Ehp, and Sbi, which exert their effects primarily through
disruption of the alternative pathway (10,11,13,14). Furthermore, the inhibitory mechanism of
SCIN is also unique in that they serve to lock the structure of the C3 convertases in a more
stable yet inactive state, whereas the native regulators of complement activation factor H (fH),
decay acceleration factor, and CR1 all promote accelerated decay rates of the transiently stable
convertase assemblies (15). Though the molecular aspects of convertase “stabilization” are not
yet elucidated, recent studies suggest that binding of SCIN may restrict the conformational
flexibility of the convertase (16). In this regard, it is surprising that SCIN proteins achieve this
strong inhibitory effect on the convertase even though they do not appear to bind directly to
any complement components other than the fully assembled convertases (8). This is very
unusual because all known inhibitory proteins that affect the structure/function of C3
convertases under either normal or pathological states must also bind directly to one or more
of the proteins (or their precursors) that are present in the convertase assembly to exert their
activities.
This prompted us to investigate the nature of the protein-protein interactions that lie at the heart
of the SCIN mechanism. Surprisingly, we observed that active members of the SCIN family
bind directly to C3b with nanomolar affinity. Further competition binding studies revealed that
the SCIN binding site overlaps with that of fH and factor B (fB) on C3b, a result which suggests
that SCIN locks the C3 convertase complex in an inactive state and prevents its accelerated
decay by blocking fH binding to the convertase-bound C3b substituent. These findings support
and extend our knowledge about the inhibitory mechanism of SCIN and may offer new
opportunities for studying S. aureus virulence and for developing therapeutic interventions.
Materials and Methods
Proteins
All complement proteins (C3, C3b, iC3b, fH, fB, factor D (fD), and factor I (fI)) were prepared
using established protocols. C3b, iC3b, and C3d were site-specifically biotinylated at the thiol
group of their thioester moiety as previously described (17). fH(1–4) was expressed and
purified as described recently (18), and fH(19–20) and CR2(1–15) were expressed as reported
previously (19,20).
DNA fragments encoding the predicted mature forms of SCIN (SCIN-A, SCIN-B, or ORF-D)
were amplified from S. aureus genomic DNA (strain Mu50) and subcloned into the prokaryotic
expression vector pT7HMT (21). Following sequence verification, expression vectors were
transformed into Escherichia coli strain BL21(DE3). Each protein was overexpressed, purified
by immobilized metal ion affinity chromatography under denaturing conditions, refolded by
rapid dilution, and concentrated according to previously described protocols (21). Following
removal of the affinity tag by site-specific proteolysis, the proteins were again purified by
immobilized metal ion affinity chromatography; in this case, it was the unbound fraction that
contained the recombinant SCIN proteins. The unbound fractions were exchanged into 20 mM
ethanolamine buffer (pH 9.0) and the proteins contained therein were separated by Resource
S cation exchange chromatography. The final purity of each protein was assessed by SDS-
PAGE or MALDI-TOF mass spectrometry before experimentation.
Direct binding studies between SCIN and C3 fragments
All surface plasmon resonance (SPR) studies were performed on a Biacore 2000 instrument
(GE Healthcare) at 25°C. Scrubber (version 2; BioLogic Software) was used for data processing
and evaluation. For an initial screening of C3 fragment binding to the immobilized inhibitor,
SCIN (1 µM in 10 mM sodium acetate (pH 5.5)) was attached to a CM5 chip via amine coupling
using activation and deactivation contact times of 5 min. Solutions of 1 µM C3b, fB, and fD
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alone as well as mixtures of C3b plus fB, C3b plus fD, fB plus fD, and C3b plus fB plus fD (1
µM each) were prepared in running buffer (10 mM HEPES (pH 7.4), 150 mM NaCl, 1 mM
NiCl2, 0.005% Tween 20) and injected for 3 min at a flow rate of 10 µl/min. After 5 min of
undisturbed dissociation, the surface was regenerated for 1 min with 3 mM EDTA. The signals
were referenced using the responses from a plain sensor surface and an ensemble of buffer
blank injections was subtracted from the processed data (double referencing (22)).
For a more physiological evaluation of the direct binding of SCIN to C3 fragments, thioester-
specifically biotinylated forms of C3b, iC3b, and C3d were captured on separate flow cells of
a streptavidin-covered sensor chip. A 2-fold dilution series of SCIN (1 nM-10 µM) was injected
for 1 min at 20 µl/min in PBS-T (10 mM sodium phosphate, 150 mM NaCl, 0.005% Tween
20, pH 7.4) and the dissociation was observed for 2 min. No regeneration was needed because
all signal readily returned to baseline within the dissociation phase window. For comparing
the specificity toward the three C3 fragments, the observed signals at 1 µM SCIN were
normalized by both the molecular weight and surface density of the corresponding fragment.
Solution phase binding between SCIN and C3b was evaluated by isothermal titration
calorimetry (ITC) using an iTC200 instrument (MicroCal). Both C3b and SCIN were dialyzed
against sample buffer (PBS without Tween 20). SCIN (125 µM in the syringe) was injected
into C3b (12 µM in the cell) at a cell temperature of 25°C using 19 injections of 2.5 µl(5 s),
injection intervals of 180 s, a reference power of 8 µcal/s, and a stirring speed of 1000 rpm.
Thermograms were evaluated using Origin (version 7; OriginLab), and the data sets were fitted
to either a “one set of sites” or “two sets of sites” model.
Structural analysis of C3b-SCIN complexes by small angle X-ray scattering (SAXS)
All protein samples were prepared in a buffer of 20 mM Tris (pH 8.0), 200 mM NaCl, 5% (v/
v) glycerol, and passed through a 0.22-µm syringe filter before data collection. SAXS data
were collected at the Advanced Light Source (beamline 12.3.1; Lawrence Berkeley National
Laboratory) (23). In particular, the wavelength, λ, was set to 1.033 Å and the sample-to-detector
distance was fixed at 1.5 m; this resulted in scattering vectors, q, that ranged from 0.008 Å−1
to 0.2 Å−1. The scattering vector is defined as 4π sinθ/λ, where 2θ is the scattering angle. All
experiments were performed at 20°C and data was processed as described previously (23).
Data acquired at both short and long time exposures (0.5 and 5 s) were merged for calculations
that required the entire scattering spectrum. Experimental SAXS data for protein
concentrations of 1 and 2 mg/ml were analyzed for potential aggregation using Guinier plots
(24). The radius of gyration, Rg, was derived by the Guinier approximation formula I(q) =
I0exp(−q2Rg2/3), where the experimental limit of qRg < 1.6 was used. SAXS curves were
measured for two C3b and C3b-SCIN concentrations (1 and 2 mg/ml), and displayed no
concentration-dependence using this criterion. The program GNOM (25) was used to compute
the pair-distance distribution function, P(r). This approach also provided the maximum particle
dimension of the macromolecule, Dmax. The molecular weights of C3b and the C3b-SCIN
complexes were determined by extrapolating each sample intensity at the zero angle and
comparing the value to a standard curve derived from four reference proteins (26). Theoretical
SAXS curves for atomic models were calculated by CRYSOL and compared with the
experimental curve as originally described by Svergun et al. (27). To further dissect the nature
of the C3b-SCIN interaction, scattering data from this complex were analyzed with the program
OLIGOMER (28). This program fit the experimental scattering curve to weighted distribution
of the theoretical scattering curves for free and dimeric C3b, using a crystal structure of C3b
(Brookhaven Protein Data Bank (PDB) code 2I07 (29)) as a model. A plausible structure for
a C3b dimer was prepared by rotation of the C3b molecule along the crystallographic 2-fold
symmetry axis (c = 147.03 Å); this orientation was chosen because it is the only solution that
describes the physiological scenario in which two C3b molecules are immobilized on a
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continuous surface via their thioester-containing domain (TED). Best-fit solutions obtained by
deconvolution of these components suggest that the sample exists as a mixture of the
components. ORF-D was used as a negative control in SAXS experiments (9,13).
Competition assays with fH and fB
The ability of SCIN to compete with fB for binding to C3b was investigated using SPR. For
this purpose, a constant concentration of fB (500 nM) in a 5-fold dilution series of SCIN (from
4 nM to 12.5 µM; i.e., molar ratio of fB to SCIN from 125:1 to 1:25) was injected for 1 min
at 20 µl/min in running buffer (PBS-T). After 3 min of dissociation, the surface was regenerated
by consecutive injections of 2 M NaCl and 0.2 M sodium carbonate (pH 9.0) for 30 s each.
The signal intensity immediately before injection end was evaluated, and the responses of the
pure SCIN series were subtracted from the corresponding competition signal. These corrected
signals were divided by the responses of fB alone (500 nM; i.e., 100% binding) to determine
the residual binding. The same experiment was repeated with fH (500 nM) and the competitive
strength of SCIN toward both complement factors was compared.
Cofactor activity assay
Because SCIN may interfere with the functionality of fH to act as a co-factor for fI in the
degradation of C3b, this possibility was assessed both on the surface and in solution. In an SPR
assay, a mixture of fI (0.4 µM) and fH (0.4 µM) in presence or absence of SCIN (1 µM) was
injected for 10 min at 2 µl/min and 25°C to immobilized C3b. To monitor the conversion of
C3b to iC3b, solutions of fH(1–4), fH(19–20), and CR2 (1 µM each) were injected before and
after enzyme treatment and their relative signals were evaluated. In addition, the inhibition of
cofactor activity in solution was investigated using a SDS-PAGE-based cofactor assay as
described (30).
C3 convertase formation, stabilization, and function
SPR was used to dissect the molecular effect of SCIN on the C3 convertase. In an on-chip
convertase formation assay, a 1:1 mixture of fB and fD (100 nM each) was injected onto
thioester-immobilized C3b on a streptavidin-coated chip for 2 min at 10 µl/min to establish C3
convertase formation. The regular convertase decay was observed for 1 min before either SCIN
(1 µM) or a buffer control was injected for 1 min. Finally, fH(1–4) (1 µM) was injected to
accelerate convertase decay, and the postinjection baseline was compared.
To assess the effect of SCIN competition with fB during convertase formation, the convertase
was formed by injecting fB plus fD in presence or absence of SCIN as premixed solutions. The
association and decay phases of the respective C3 convertases were evaluated and compared.
Finally, the ability of the SCIN-stabilized convertase to bind and cleave native C3 was
compared with the unmodified convertase. For this purpose, C3b was immobilized to a CM5
sensor chip via amine coupling and the convertase was formed on-chip as earlier described.
Native C3 was injected for 1 min onto the established convertase, and both the slope and
postinjection increase in baseline were monitored. SCIN (1 µM) or a buffer control was injected
for 1 min, and the injection of native C3 was repeated.
Results
SCIN binds directly to C3b
SCIN was previously described to bind to the assembled alternative pathway C3 convertase
(i.e., C3bBb) but not to any of its individual components (8,13). Indeed, when SCIN-A was
immobilized on a sensor chip surface via random primary amine groups, no significant binding
was detected for C3b, fB, fD, or two-component mixtures thereof. In contrast, an SPR signal
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was observed when C3b was mixed with fB and fD in a nickel-containing buffer (Fig. 1A).
Although a similar response was noted in buffer containing magnesium, no signal was detected
in the absence of these divalent metal ions (data not shown). Together, these results strongly
suggested binding to the assembled convertase and confirmed the lack of binding for the
individual components under these assay conditions.
We likewise used a more physiological assay format, wherein C3b was site-specifically
captured on a sensor chip via its thioester group. Remarkably, soluble SCIN-A showed
substantial binding to this surface (Fig. 1B, green signal). Furthermore, although the signal
intensity was nearly identical for the inactive form of C3b (i.e., iC3b), no significant binding
was observed for the C3d fragment (Fig. 1B, blue and magenta signals). These data strongly
suggested that SCIN interacts with the C3c part of C3b, and also that the TED is not involved
in formation of this complex. Consistent with previous functional data, no interaction was
detected for the inactive member of the SCIN family, ORF-D, whereas SCIN-A and SCIN-B
bound with apparently similar activity (see supplemental Fig. S1; SCIN-A is referred to as
SCIN in subsequent experiments).5
To further characterize the interaction profile, a 2-fold serial-dilution series of SCIN (0.8
nM-12.5 µM) was injected on immobilized C3b. SCIN showed dose-dependent binding with
rather fast kinetic on- and off-rates (Fig. 1C). Although clear signs of saturation were seen in
the selected concentration range, both the signal intensity and shape deviated slightly from a
simple 1:1 model, especially at higher concentrations. To estimate the affinity of the interaction,
the “steady-state” phases were evaluated; this analysis revealed a reasonable fit to a single-
binding site model with an apparent KD of 177 nM (Fig. 1, D and Table I). Although the quality
of fit for the experimental data was improved significantly when a two-binding site model was
applied (see supplemental Fig. S2),5 no quantitative assessment of the two affinity constants
was performed due to the lack of concentration coverage. Similarly, kinetic analysis of these
data sets revealed deviations from a pure Langmuir 1:1 binding model, particularly in the
association phase (data not shown). Nevertheless, a kinetic off-rate of 0.09 s−1 could be
extracted, which translates to a rather short dissociation half-life of nearly 10 s. When compared
with the 60-min half-life for the C3b-Efb-C complex (10), the kinetic stability of the C3b-SCIN
complex is much lower. As might be predicted by the highly electropositive nature of SCIN,
the interaction with C3b was dependent on the ionicity of the buffer system. This suggests that
electrostatic steering effects contribute substantially to the interaction (see supplemental Fig.
S3),5 as has also been reported for the C3d-Efb-C complex (31). To examine separately the
binding event between C3b and SCIN in solution and to characterize its thermodynamic profile,
we also performed an ITC study. Injection of SCIN into C3b generated clear exothermic
binding signals that resulted in saturation (Fig. 1E), and therefore demonstrated that SCIN
binds to C3b in solution. Even though the data set could be fit to a single set of sites with a
KD of 264 nM and an enthalpy of ΔH = −7 kcal/mol, the stoichiometry value of N = 0.75 again
indicated a deviation from a pure 1:1 model (Fig. 1F and Table I).
The observed deviations from a 1:1 binding model were further investigated using SAXS,
which has evolved into a powerful tool to achieve structural information on protein-protein
interactions in solution. This technique is sensitive to changes in protein conformations and
can also be used to better understand defined monomer-to-oligomer transitions that occur upon
binding. To examine the interactions between C3b and SCIN, we collected SAXS data on C3b
alone and in the presence of either SCIN or ORF-D (Fig. 2 and Table II). The pair-distance
distribution functions, P(r), derived from the scattering curves for C3b alone or in the presence
of equimolar (but nonbinding) ORF-D were indistinguishable. In contrast, the pair-distance
distribution function for C3b-SCIN was consistent with substantial increases in the particle
5The online version of this article contains supplemental material.
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size of this complex, as judged by changes in both the radius of gyration (Rg) and the long-
tailing nature of the pair-distance distribution function (Fig. 2A). Estimation of the observed
molecular weight for each sample by calculating the normalized scattering intensity at zero
angle (q = 0; I0) relative to four standard, control proteins (Table II) (see supplemental Fig.
S4),5 revealed a nearly 40% increase in the apparent mass of C3b-SCIN relative to the ORF-
D control or C3b alone. This change was surprising because SCIN binding to C3b was expected
to increase the theoretical molecular mass of the complex by less than 5% relative to C3b alone.
The results from direct binding studies presented above suggested that although equimolar, the
C3b-SCIN complex might exist as equilibrium between 1:1 and 2:2 species. Given the
unexpectedly large molecular weight of C3b-SCIN derived from the scattering curve (Table
II), we examined whether this complex might be composed of a defined mixture between
heterodimeric and heterotetrameric species. The program OLIGOMER was used to
deconvolute the experimental C3b-SCIN scattering curve into a weighted distribution of the
theoretical scattering curves for free and dimeric C3b (Fig. 2, B and C). Although this analysis
for C3b alone confirmed that the scattering curve was described well by the crystal structure
of C3b (χ2 = 4.5), we found that the C3b-SCIN complex existed most likely as a percentage
40:60 distribution of tetrameric to dimeric species (χ2 = 3.2). It has to be noted that the small
deviation of calculated and experimental scattering observed at high scattering vector (q >
0.18Å−1) may be due to intrinsic flexibility of C3b in solution relative to its crystal structure.
This ability may lead to additional variability in the conformations of C3b and probably resulted
in the observed deviation in the high scattering vector range. Nevertheless, these SAXS data,
in conjunction with the binding studies described, demonstrated that SCIN binds directly to
purified C3b, and strongly suggested that the complex exists as an equilibrium mixture of 1:1
and 2:2 species.
SCIN binds to an area near the C terminus of the C3b β-chain
The ability of SCIN to bind C3b and iC3b but not C3d indicated that the SCIN binding site is
located within the C3c fragment and not the C3d/TED of C3. In agreement with this
observation, formation of a stable complex between C3b and Efb-C, which is known to bind
to the TED, did not significantly influence the interaction with SCIN (Fig. 3, blue). In contrast,
complex formation with the monoclonal anti-C3c Ab C3–9 almost completely eliminated
binding of SCIN to C3b, which confirms the localization on the C3c segment (Fig. 3; red). As
negative-stained EM imaging has previously defined the binding area for mAb C3–9 to the
vicinity of the β-chain C terminus (i.e., macroglobulin (MG)7/8 domains) (32), a SCIN binding
site at or in the proximity of a similar region of C3b seems likely.
SCIN competes with complement fB and fH for C3b binding
Previous observations suggested that SCIN binds the C3bBb convertase complex and locks it
in an inactive state (8). It is therefore reasonable that SCIN may bind to an area on C3b that is
adjacent to the contact region for fB (or its Bb fragment). In contrast, the complement regulator
fH is known to accelerate decay of the convertase by competing with Bb for C3b. As a
consequence, a shared binding region for fB, fH, and SCIN on C3b seemed highly likely. We
therefore performed a series of solution competition experiments with SCIN and both fB and
fH for binding to C3b (Fig. 4). For this purpose, a constant concentration of the respective
complement factor was mixed with increasing concentrations of SCIN and injected onto a
biosensor surface on which C3b had been uniformly immobilized via its thioester group. If
SCIN and the complement factor bound independently, the resulting SPR signal should be
additive. In the case of both fB (Fig. 4A) and fH (Fig. 4B), subtraction of the pure SCIN response
revealed a significantly lower binding response in the presence of the inhibitor. The most
straightforward interpretation of these data is that SCIN, fB, and fH all compete for an
overlapping binding site on C3b. In contrast to fH, which was almost completely inhibited at
Ricklin et al. Page 7
J Immunol. Author manuscript; available in PMC 2010 August 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
a 25-fold molar excess of SCIN, the binding of fB to C3b was only partially restricted at the
same ratio (Fig. 4C).
SCIN inhibits the degradation of surface-bound C3b by fl and fH
The strong competition with fH for binding to C3b suggested that SCIN might interfere with
the activities of this complement factor. As the major regulator of the alternative pathway of
complement activation, fH suppresses complement activation on host cells by both
destabilizing the convertase (decay acceleration activity) and acting as a cofactor for fI-
catalyzed degradation of C3b to iC3b (cofactor activity). We therefore tested the influence of
SCIN on the cleavage of surface-bound C3b by fI plus fH using an SPR assay. Differential
ligand binding was used to monitor the progress of degradation; although the N-terminal
fragment of fH (i.e., fH(1–4)) is known to lose activity after the conversion of C3b to iC3b,
CR2 shows a clear selectivity for iC3b over C3b. The C terminus of fH (i.e., fH(19–20)) was
not expected to change activity at all and was included as a negative control. Indeed, when the
three ligands were injected onto immobilized C3b, only the two fH fragments showed
significant binding. After premixed fI and fH were injected for 5 min, the binding pattern
changed completely between fH(1–4) and CR2 (Fig. 5A). When SCIN was added to the fI plus
fH mixture, the extent of degradation of C3b was significantly lower (Fig. 5B, dotted line).
Subsequent injection of the uninhibited enzyme mixture again led to the full extent of cleavage
(Fig. 5B, dashed line). Although the removal of the C3f fragment during the conversion of C3b
to iC3b was also visible as a drop in the mass of the surface-bound protein, the rate and extent
of this mass decrease was much lower in the presence of SCIN (see supplemental Fig. S5).5
An SDS-PAGE-based assay system was used to detect a corresponding effect on cofactor
activity of fH in solution. However, the inhibitory effect of SCIN was very low even at a 50-
fold molar excess of SCIN over fH (data not shown). This discrepancy in cofactor inhibition
may be either based on the sensitivity of the assay system or a result of differential activity for
SCIN toward surface-bound and solution-based C3b, as has been observed for Efb-C (13).
SCIN binds to and prevents decay of the assembled convertase
Due to its competition with both fB and fH, SCIN is expected to have direct consequences on
the formation and stability of the C3 convertase. As previously demonstrated, the assembly
and decay of the convertase can be monitored directly on a SPR sensor chip when a mixture
of complement fB and fD is injected over immobilized C3b (18,33,34). In the analyses shown
in Fig. 1A, the C3 convertase readily formed when the two factors were injected on thioester-
specifically immobilized C3b and showed a decay half-life of 5–6 min in magnesium-
containing buffer at 25°C. Injection of fH(1–4) induced a large acceleration of this decay as
indicated by a drop of the postinjection signal to near-baseline levels (Fig. 6A, solid line). When
SCIN was injected after a short stretch of regular decay, the inhibitor rapidly bound to the
assembled convertase and significantly slowed down the decay phase (Fig. 6A, dashed line).
Even more, the subsequent injection of fH(1–4) had nearly no effect on the signal (Fig. 6A,
dashed line). This indicated that SCIN not only slows down the regular decay of the convertase
but also prevents accelerated decay by fH.
Separately from its stabilizing effect on the assembled C3 convertase, the direct competition
of SCIN with fB previously observed (Fig. 4) may also affect formation of the C3 convertase.
We therefore preincubated SCIN with fB plus fD and monitored formation of the convertase
in the presence of SCIN. Indeed, the rate of complex formation was slightly but significantly
reduced in presence of the inhibitor (Fig. 6B, dashed line). The convertase formed in this
manner again exhibited a much slower decay phase when compared with the same experiment
in absence of SCIN (Fig. 6B, solid line). In summary, these results indicate that binding of
SCIN to a site in proximity to the binding areas for fH and fB affects both the formation and
decay of the surface-assembled alternative pathway C3 convertase.
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SCIN prevents the cleavage by but not the binding of C3 to the convertase
To exhibit any inhibitory effect on C3 activation, binding of SCIN to the convertase must result
in a complex that is incapable of generating C3b. Cleavage of C3 has been shown to generate
a very short-lived acyl-imidazole species at the thioester moiety that binds covalently to amine-
and hydroxyl-rich patches on cellular surfaces. It has previously been shown that the
carboxymethyl dextran-based matrix of SPR sensor chips is accepted as a target surface and
that C3b deposition can be observed when C3 is injected onto the assembled convertase (34).
We therefore formed the C3 convertase as described and injected native C3 during the decay
phase (Fig. 7). After a short and rapid signal increase, a slower but steady increase followed
that indicated deposition of C3b. After the injection cycle ceased, the baseline remained at a
significantly higher level due to the covalently bound C3b (Fig. 7A, solid line). Because of the
ongoing decay of the convertase, a second injection with C3 generated a similar yet smaller
increase. After regeneration of the convertase by fH(1–4), the complex was freshly formed by
another injection of fB plus fD. This time, the formation rate was slightly higher due to the
additional C3b on the surface. Again, a first injection of native C3 led to deposition of C3b.
However, when SCIN was injected to the assembled convertase, the subsequent injection of
C3 only generated a small binding response but not deposition of C3b (Fig. 7A, dashed line).
These findings suggested that SCIN does not prevent the initial binding of C3 to the convertase,
but instead inhibits its cleavage to active C3b.
Discussion
SCIN is one of the most potent inhibitors of complement activation identified to date and may
be an important determinant in the virulence of S. aureus. Previous studies have identified the
C3 convertases of the alternative and classical complement pathways (C3bBb and C4b2a,
respectively) as primary targets for this inhibitor (8,13), and demonstrated that SCIN inhibited
the activation of all three complement pathways, opsonization by C3b, phagocytosis, bacterial
killing by neutrophils, and generation of C5a (8,13). Despite this wealth of information about
the functional implications of SCIN, its binding mode and molecular mechanism remained
elusive. In this study, we focused our attention on molecular effects of SCIN on the alternative
pathway, as this pathway is responsible for a majority of the usually observed complement
response through its amplification loop (35). In addition, more structural and functional data
are available for this pathway, which facilitates a more informative interpretation and
correlation of our experimental data. While dissecting the molecular targets of SCIN, initial
binding studies indicated that SCIN only binds to the assembled convertase complex (e.g.,
C3bBb) but not to individual proteins (i.e., C3b and fB) or to the proenzyme complex C3bB
(8). Considering the high activity and specificity of the inhibitor, as well as its structural
similarity to C3b-binding proteins from S. aureus (4), this selectivity for the convertase was
rather surprising. When using a similar assay setup with immobilized SCIN on a sensor chip
and complement fragments in solution, we could indeed reproduce this selectivity in our study
experiments (Fig. 1A). However, this model only poorly describes the in vivo situation in which
C3b and C4b are firmly attached on cell surfaces and form the respective convertases, and in
which the rather small and highly charged SCIN protein might interact more freely with these
surface structures. In an attempt to mimic these conditions, we specifically immobilized C3b
via its thioester to a sensor chip and injected SCIN in solution. Using this reversed experimental
format, SCIN indeed showed concentration-dependent binding to C3b with nanomolar affinity.
Although the different results obtained from these inverted assay formats are surprising, they
are not without explanation. First, surface-immobilized SCIN may suffer from a partial
inactivation during the random amine immobilization procedure. Examination of the SCIN
sequence indeed reveals the presence of two lysine residues (Lys41 and Lys45) within its
reported active site (9). Modification of these locations may well have altered the affinity and
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selectivity of the protein. Secondly, surface attraction effects may also contribute to this
discrepancy. Much like the cell wall of S. aureus (36), the carboxymethyl dextran matrix of
the sensor chip exhibits a negative net charge and is rich in hydroxyl groups (37). Previous
studies have shown that such SPR surfaces are readily recognized as targets for C3b
opsonization (34,38). The highly electropositive SCIN (pI ≈ 9) may therefore be attracted to
and enriched at the surface, thus leading to a stronger apparent affinity toward C3b. In its
biological environment, such a behavior makes sense because soluble SCIN, although secreted,
is supposed to inhibit complement convertase activity at the surface of S. aureus. A similar
effect may also be responsible for the observation that Efb-C and Ehp, which are similarly
electropositive, primarily act on surface-bound rather than fluid phase convertases (13). Here
again, these inhibitors may be enriched at the surface of S. aureus or on zymosan, which were
both used in the study.
Although the effect of surface attraction may also be reflected in the small, but significant
difference in affinity between SCIN binding to surface-bound C3b (i.e., SPR) and soluble C3b
(i.e., ITC), our ITC results clearly demonstrate that surface attraction is not a requirement for
this interaction and that SCIN alone possesses a strong binding affinity for C3b. The observed
KD values in the range of 170–265 nM are weaker than those of the structurally similar Efb-C
protein (i.e., 1–2 nM) (10) but are clearly stronger than for domains III-IV of Sbi (14), which
also belongs to this structural family (i.e., 1.4 µM for C3dg and weaker still for C3b). In both
binding assays, the C3b-SCIN interaction slightly but significantly deviated from a 1:1 binding
model. In the case of SPR, this effect was more pronounced at the higher SCIN concentrations
we used. As heterogeneity effects could be largely excluded (high purity of the proteins,
oriented immobilization or solvent state of all analytes), the availability of two separate binding
sites with different affinity is more likely. Extrapolation of the SPR fit to a two-binding site
model (see supplemental Fig. S2)5 suggests a KD of greater than 200 µM for the low-affinity
site. However, neither the SPR nor the ITC assays are capable of covering such a high
concentration range, which makes an exact determination of this value unfeasible.
Nevertheless, this additional binding site is likely to explain the deviations from the 1:1 model,
and cooperative binding of two SCIN and two C3b molecules might lead to the formation of
rather stable dimeric complexes in solution. This hypothesis was further supported by the
solution scattering data, which clearly indicated that SCIN and C3b are forming both 1:1 and
2:2 complexes. In addition, the recent description of low-resolution crystal data for the C3b-
SCIN complex also revealed a rather large unit cell that was consistent with the presence of
either two 1:1 complexes or a single 2:2 complex in the asymmetric unit (39). Most importantly,
our findings are in agreement with structural data from the inhibited alternative pathway C3
convertase, in which SCIN is in contact with two C3b molecules and forms highly stable
SCIN2C3b2Bb2 complexes (16).
The fact that SCIN interacts with both C3b and iC3b (with similar activity) but not with C3d
clearly indicates that the binding site for the inhibitor must be located at the C3c domain. The
nearly complete blockage of the SCIN-C3b interaction by the anti-C3c mAb C3–9 not only
confirmed this observation but also allowed us to further resolve the primary binding site.
Electron microscopy studies with the F(ab)2 fragment of mAb C3–9 have shown that this Ab
binds to an area around MG7 and MG8 domains on C3b, which undergoes a large
conformational transformation upon activation of C3 to C3b (32). Indeed, formation of this
neo-epitope allows mAb C3–9 to distinguish between native C3 and active C3b (40). The direct
competition with this mAb for C3b binding strongly suggests that SCIN binds to a similar area
at the C terminus of the β-chain of C3b. The functional importance of this region has been
demonstrated earlier, as both mAb C3–9 and a novel therapeutic anti-C3b mAb (S77), which
primarily binds to MG7, block the binding of all fH, fB, and CR1 to C3b (41,42). In the case
of fH, we have recently shown that mAb C3–9 only blocks the binding of the N-terminal four
domains (fH(1–4)) but the not the C-terminal domains (fH(19–20)) (18). These four domains
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are sufficient for both regulatory properties of fH, i.e., the acceleration of convertase decay
and the cofactor function for fI (43).
We therefore investigated whether the potential binding of SCIN to a similar region would
allow the inhibitor the activity of fB and fH and found that both factors are substantially
inhibited by SCIN for their binding to C3b. Interestingly, the degree of this competition effect
was distinct for the two complement proteins. Although fH was nearly completely blocked at
a 25-fold molar excess of SCIN, the binding of fB was only partially competed and leveled off
at around 30% residual binding. This observation is in agreement with the known mechanism
of SCIN to lock the convertase in an inactive state, which requires that the Bb domain is still
associated with C3b and not replaced by SCIN. It is therefore more likely that SCIN partially
restricts the initial binding of full-length fB to C3b via its Ba domain. Even though this
competition with fB did slightly influence the formation rate of the convertase complex on the
chip (Fig. 6B), the effect on the stability and function of the assembled convertase is more
striking. When added to the C3bBb complex, SCIN bound rapidly and decreased the decay
rate of the convertase (Fig. 6A). Even more importantly, the SCIN-stabilized convertase was
unable to cleave C3, as no C3b deposition to the chip surface could be detected in the presence
of SCIN (Fig. 7). As a consequence, we can now confirm earlier hypotheses that SCIN locks
the convertase in an inactive state (13) at a molecular level.
Interestingly, C3 still seems to be able to bind the convertase (as indicated by a block-shaped
signal upon injection; Fig. 7B), which suggests that only contact and cleavage through the
enzymatic entity (i.e., Bb) but not the initial binding to the convertase is inhibited by SCIN.
When combining this information with recent structural studies about the C3 convertase and
the complement inhibitor compstatin (16,44), it emerges that the area around MG4/5 is more
important for this initial binding, whereas the primary SCIN binding site around MG6–8 is
essential for the functional activity of C3b or the convertase. Binding of SCIN at this area forms
a trimeric complex with C3b and Bb (16), which explains the much slower convertase decay
observed in our study. Although it was speculated that SCIN might inhibit the convertase by
either preventing substrate binding or hindering essential domain movements that allow cleave
of C3 (16), our data indicate that binding of C3 is still possible and are therefore in favor of
the conformational hypothesis. The observation that the SCIN-stabilized convertase appears
to exclusively form a dimeric complex (SCIN2C3b2Bb2) in solution (16) opened the question
of whether this dimerization is required for blocking the convertase. In this regard, ligand
density and uniform immobilization of C3b molecules in our SPR assay makes it highly
unlikely that any dimeric convertase assemblies could form. We therefore conclude that SCIN
is able to inhibit the surface-bound convertase in its monomeric form.
In the case of fH, we observed that binding of SCIN to C3b or to the C3 convertase affects
both key regulatory functions of the factor. First, the ability of fH to act as a cofactor for fI in
the cleavage of surface-bound C3b to iC3b was investigated by monitoring the change in
binding specificity for fH(1–4) and CR2, which have opposite selectivity for the active and
inactive form of C3b (45,46). Addition of SCIN to the enzyme/cofactor mix partially inhibited
the conversion to iC3b as visible both in a lower mass loss caused by removal of the C3f
fragment (see supplemental Fig. S5)5 and in a less pronounced change in binding selectivity
toward CR2 (Fig. 5). The functional relevance of this inhibitory effect is difficult to judge
because it may require rather high local SCIN concentrations and S. aureus may actually benefit
from the degradation of C3b. However, iC3b and its downstream fragment C3d are both able
to participate in signaling pathways and keeping C3b locked up in the convertase may be
advantageous. Perhaps more important for the functional properties of SCIN is that this
bacterial protein effectively eliminates the ability of fH(1–4) to accelerate the decay of the
convertase (Fig. 6). Again, this observation is in good agreement with the direct and complete
competition between SCIN and fH for C3b binding as described. As a consequence, SCIN not
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only decelerates the decay of the inactive C3bBb complex but also makes it insensitive for an
intercalation by fH to remove the Bb fragment (Fig. 8). In solution, binding of SCIN to C3b
will likely induce dimeric convertase complexes and therefore impair complement activation
in circulation (16). It has to be further investigated, though, whether other SCIN-mediated
effects such as impairing cofactor activity of fH are relevant in solution, especially because
they are expected to require rather high concentration to be effective (as e.g., seen in the case
of the solution-based cofactor assay using SDS-PAGE).
In summary, our data clearly demonstrate that SCIN directly interacts with C3b at a functional
“hot spot” on this central complement component and thereby exerts a variety of its functional
and inhibitory activities. Of these, entrapment of the C3 convertase complex in an inactive
state that does not allow cleavage of C3 has to be considered the most important and effective
immune evasion strategy. Though “stabilization” of the central active entity in the cascade (C3
convertase) and “inhibition” of a potent down-regulator (fH) appears highly contradictory for
a microorganism, S. aureus has developed a malicious yet ingenious strategy to turn these
actions to its advantage (Fig. 8). In fact, the bacterium profits much more from a locked,
dysfunctional convertase rather than an intact decay acceleration activity because the former
case not only leads to a direct inhibition of the C3b self-amplification loop but may also block
C3b from participation in any proinflammatory downstream activities of the cascade. Still,
SCIN may also influence additional complement functions by competing with fH and fB (and
possibly other regulators) for binding to C3b, some of which may benefit complement evasion
(e.g., slowing the rate of convertase formation) and some of which may be less obvious or mere
“side effects” of its successful inhibition (e.g., inhibition of cofactor activity of fH) (Fig. 8).
Our data also suggest that electrostatic effects may contribute to an increased activity of SCIN
around negatively charged surfaces (such as the S. aureus cell wall). The versatility and high
activity of its inhibitory effects not only put SCIN into the spotlight for elucidating its
contribution on the virulence of S. aureus but also renders it into an interesting molecular
template for the design of novel therapeutics against complement-mediated diseases (4,15). In
this regard, more molecular details about the binding interface, the exact mechanism of
blocking C3 cleavage and its effects on the classical pathway convertase or the C5 convertases
should be addressed in future studies.
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FIGURE 1.
SCIN binds to both surface-bound and solution-based C3b with nanomolar affinity. A, When
SCIN was immobilized on a SPR chip surface, only the convertase mix (C3b plus fB plus fD)
showed significant affinity. B, In contrast, solution-based SCIN (1 µM) bound with similar
activity to C3b (green) and iC3b (blue) that have been immobilized via their thioester moiety
to the SPR sensor chip. No significant binding was observed for C3d (magenta). C, The binding
mode and affinity of SCIN was further elucidated using SPR by injecting a dilution series of
SCIN (0.8 nM–12.5 µM) to site-specifically immobilized C3b. Despite some heterogeneity at
higher concentrations, the interaction featured reproducible triplicate injections (black SPR
signals) and fitted reasonably well to a Langmuir 1:1 kinetic model (red fitting curves). D, In
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agreement with the kinetic analysis, the steady state signals (black filled symbols) could be
fitted to a single-binding site model and showed clear signs of saturation (red fitting curve). A
direct interaction between SCIN and C3b was also detected in solution using ITC. E, Injection
of SCIN (120 µM) into C3b (12 µM) produced a dose-dependent, exothermic response. F, The
integrated data (filled black symbols) could be fitted to a single set of sites (red fitting curve).
RU, Resonance units. A schematic representation of the assays is available (see supplemental
Fig. S6, A–C).5
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FIGURE 2.
SCIN and C3b form a mixture of monomeric and dimeric complexes when analyzed by SAXS.
A, Pair-distance distribution function (P(r)) calculated for scattering data collected on solutions
of C3b-SCIN (black), C3b-ORF-D (red), and C3b alone (blue). Note the shift in r(Å) value,
where pair-distance distribution function is maximal and the long-tailing pair-distance
distribution function curve for C3b-SCIN relative to the control samples. B, Experimental
scattering curve of unliganded C3b observed in solution (black) compared with the theoretical
scattering curve for an unliganded C3b crystal structure (PDB code 2I07 (29)). C, Guinier
analysis of the C3b-SCIN experimental data as compared with theoretical scattering curves for
a sample comprised entirely of C3b dimer (green) or 40/60 percentage C3b dimer to C3b
monomer (red), as determined by the program OLIGOMER (28). The value for the quality of
fit parameter (χ2) is shown in B and C.
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FIGURE 3.
The SCIN binding site can be localized at a functionally important area on C3b. A, The binding
of SCIN to immobilized C3b was compared in the presence or absence of mAb C3–9 (anti-
C3c) and the bacterial complement inhibitor Efb-C. Whereas SCIN bound similarly well to the
C3b-Efb-C complex (blue) compared with free C3b (green), mAb C3–9 led to a significant
decrease in binding activity (red). B, The domains involved in binding of mAb C3–9 (MG7,
MG8 (32)), Efb-C (TED (10)), and the fragment fH(1–2), and Ba (α′NT, MG6, MG7 (18))
have been highlighted on the crystal structure of C3b (PBD code 2I07 (29)). A schematic
representation of the assays is available (see supplemental Fig. S6D).5
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FIGURE 4.
SCIN competes with fB and fH for binding to C3b. In an SPR experiment, constant
concentrations (500 nM) of either fB (A) or fH (B) in HBS-Mg buffer were injected to
immobilized C3b either alone (black line) or as mixtures with increasing concentrations (20
nM–12.5 µM) of SCIN (light gray line). The same dilution series of SCIN alone (dark gray
line) was injected and subtracted from the corresponding signal of the fB plus SCIN mixture
(dashed curve). For reasons of simplicity, the plots show only one concentration of SCIN (2.5
µM) and fB or fH (500 nM). C, The residual signals for both competition series were divided
by the uninhibited fB or fH response and plotted against the molar ratio between SCIN and fH
or fB concentrations. Although both complement factors compete with SCIN for binding to
C3b, the effect is significantly more pronounced for fH than fB. A schematic representation
of the assays is available (see supplemental Fig. S6, E and F).5
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FIGURE 5.
SCIN inhibits the cofactor activity of fH. A, The fI-mediated degradation of surface-bound
C3b by fI was observed by using SPR with fH(1–4) as a probe for intact C3b and CR2 for
degraded C3b (i.e., iC3b). fH(19–20) was used as a control that is not affected by the cleavage.
After sequential injection of the three probes over intact C3b (solid curve), a degradation
mixture of fI plus fH was injected, and the probes were assessed again (dashed curve):
degradation of C3b to iC3b was manifested in an impairment of fH(1–4) binding with a
simultaneous increase in CR2 activity. B, The SPR experiment in A was repeated with the same
degradation mixture in presence of SCIN. Injection of this mixture led only to a partial
degradation with significantly lower effects on fH(1–4) and CR2 (dotted curve). When the
Ricklin et al. Page 21
J Immunol. Author manuscript; available in PMC 2010 August 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
degradation mixture was injected in absence of SCIN, full degradation could be achieved again
(dashed curve). A schematic representation of the assays is available (see supplemental Fig.
S6G).5
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FIGURE 6.
SCIN influences the formation, decay, and stability of the alternative pathway C3 convertase.
A, The on-chip formation and decay of the C3 convertase was established by injecting a 1:1
mixture of fB and fD (100 nM each) onto immobilized C3b using SPR (solid curve). After
injection end (2 min), a moderate decay of the convertase could be observed, which was greatly
accelerated upon injection of fH(1–4) (1 µM). When SCIN (1 µM) was injected after formation
of the convertase (dashed curve), the inhibitor bound to the complex, slowed the decay rate,
and impaired the decay accelerating action of fH(1–4). B, When SCIN (1 µM) was added to
the fB plus fD mixture, it partially reduced the formation of the C3bBb complex, and showed
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the same effect on the stability and fH(1–4) resistance as in A. A schematic representation of
the assays is available (see supplemental Fig. S6H).5
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FIGURE 7.
SCIN prevents C3 cleavage and C3b deposition by the C3 convertase. A, In a first cycle (solid
curve), the C3 convertase was formed by injecting fB plus fD over immobilized C3b. When
native C3 was injected, an initial sharp signal increase corresponding to C3 binding to the
convertase and a slower binding slope representing deposition of cleaved C3b on the sensor
chip surface could be observed (see schematic representation in panel B). After a buffer
injection, C3 was injected again and a similar yet smaller slope could be detected (due to the
regular decay of the convertase). In a subsequent cycle (dashed curve), a higher convertase
formation rate was observed due to the previously deposited C3b. Again, injection of C3 led
to binding of C3 and deposition of cleaved C3b. However, after SCIN was injected to the
convertase, only C3 binding but no deposition of cleaved C3b was detected, therefore
indicating that SCIN prevented the activation of C3 to C3b by the convertase. A schematic
representation of the assays is available (see supplemental Fig. S6I).5
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FIGURE 8.
Potential effects of SCIN on complement activation and regulation. A, During normal
complement activation, fB binds to C3b (1) and is converted to the C3 convertase (C3bBb) by
fD (2). Native C3 binds to the convertase complex (3), becomes cleaved by Bb (4), and the
resulting C3b is deposited on the surface (5). Surface-bound C3b can again participate in
convertase formation (self-amplification) or can be degraded by fI and fH (6) to iC3b, which
does not bind fB but is still involved in signaling (7). Finally, fH also regulates complement
activity by accelerating the decay of the C3 convertase (8). B, By binding at a focal point on
C3b, SCIN seems to interfere with this response in various ways: it slows down convertase
formation but kinetically stabilizes the convertase complex in a state in which C3 can still bind
but does not get cleaved. It also impairs the actions of fH by preventing decay acceleration and
potentially decelerating the degradation to iC3b.
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Table I
Thermodynamic and kinetic profile of the direct interaction between SCIN and C3ba
kon (105/M s) koff (10−2/s) KD,KIN (nM)b KD,SS (nM)c KD,ITC (nM)d ΔHITC (kcal/mol)d
SCIN-A 5.5 ± 0.9 9.1 ± 1.7 169 ± 34 177 ± 34 264 ± 6 −7.1 ± 0.5
a
Profile measured using SPR and ITC. Data are mean affinity ± SD.
b
Calculated as KD = koff/kon; concentration range from 0.8 nM to 12.5 µM; Langmuir 1:1 binding model.
c
Determined from steady state plot; concentration range from 0.8 nM to 12.5 µM; single-binding site model.
d
Fitted to a “one set of sites” model with stoichiometry; N = 0.75 ± 0.09 and entropy; ΔS = 6.3 ± 1.7 cal/mol.
J Immunol. Author manuscript; available in PMC 2010 August 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Ricklin et al. Page 28
Table II
Dimensional constants for C3b and SCIN complexes derived from SAXS data
Sample Rg (Å)a Dmax (Å)b Molecular Mass (kDa)c
C3b 46.9 160 185
C3b-ORF-D 47.6 160 188
C3b-SCIN 54.2 215 265
a
Radius of gyration (Rg) given by the Guinier approximation (45).
b
Dmax is maximum protein distance estimated from pair-distance distribution (P(r)) function.
c
Calculated from molecular mass versus I0/concentration relationship (see supplemental Fig. S4).5
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